undamentalytics Newsletter
Sign in

Eton Pharmaceuticals, Inc. income statement

In fiscal 2025, Eton Pharmaceuticals, Inc. reported revenue of $80.0m, up 104.9% on the year before, operating income of −$844,000 (a -1.1% margin) and net income of −$4.6m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue102221323980106
Cost of revenue003711163744
Gross profit1−0191421234361
Research and development1214643386
General and administrative813141919233639
Operating income−19−27−1−8−1−3−116
Interest expense0111125—
Income before tax−18−28−2−9−1−4−513
Income tax——000000
Net income−18−28−2−9−1−4−513
Diluted EPS−$1.03−$1.33−$0.08————$0.43
Diluted shares (average)18m21m25m25m26m26m27m30m
EBITDA−18−27−1−8−0−1321

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ETON vs NAGEETON vs ZVRAETON vs NAII

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Eton Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Eton Pharmaceuticals, Inc.